From: Sunny Novo and

2024

Approved

Rocuronium Bromide Injection

Hi

From

No

Come on

through professional and efficient technical services, sunshine nuohe helped its partner jilin zhenao pharmaceutical co., ltd. to obtain the marketing license for "rocuronium bromide injection!

In the future, Sunny will continue to improve its professional capabilities and service levels, provide customers with more efficient, high-quality, and cost-controllable drug research and development and production services, and help more products go on the market!

Hot/Fierce/Wish/Congratulations

Rocuronium Bromide Injection

High selectivity, high safety

Clinical use of muscle relaxation anesthesia

Muscle relaxants (muscle relaxants) are drugs that act on nicotinic acetylcholine receptors in the anterior and posterior membranes (endplates) of the neuromuscular junction. Muscle relaxants act on the posterior membrane receptors of the neuromuscular junction, blocking the normal transmission of neuromuscular excitation and producing muscle relaxation.

Muscle relaxants are the primary adjunct to general anesthesia to facilitate surgical procedures, such as intubation during routine induction of anesthesia, and to maintain intraoperative skeletal muscle relaxation. Clinically commonly used muscle relaxants are divided into polarized muscle relaxants and non-polarized muscle relaxants according to different mechanisms of action. In addition to polarized muscle relaxants, succinylcholine, non-polarized muscle relaxants, in addition to rocuronium, atracurium, cisatracurium, vecuronium, piecuronium, etc.

rocuronium bromide is one of the muscle relaxants that are closest to ideal conditions in clinical application today: rocuronium bromide is a non-depolarizing muscle relaxant with low efficacy and medium aging. it has fast onset of effect. intravenous injection of 0.6 mg/kg(2 times ED95) can meet the satisfactory intubation requirements within 60~90s, and there is no obvious change in heart rate and blood pressure in clinical application dose, does not release histamine. It is mainly eliminated by the liver, and its pharmacokinetics is similar to that of vecuronium. It is a good non-depolarizing muscle relaxant for induction of intubation, especially for tracheal intubation in patients with succinylcholine contraindication.

Variety characteristics

As one of the muscle relaxants closest to ideal conditions currently used in clinical practice, rocuronium has the following characteristics:

Fast onset of action, including faster onset of action on laryngeal muscles than on skeletal muscles such as adductor thumb;

It can be used for emergency ophthalmic surgery;

It does not cause histamine release, and the incidence of allergic and anaphylactoid reactions is extremely low;

It has little effect on liver and kidney function, and there is no need to adjust the dose for patients with liver and kidney function damage;

Like other non-depolarizing muscle relaxants, it can be antagonized by cholinesterase inhibitors, and the muscle relaxant effect is easy to control.

Jilin Zhen'ao

Jilin Zhenao Pharmaceutical Co., Ltd. is the core backbone enterprise invested and constructed by Sihuan Pharmaceutical Holding Group in Jilin Province. It is located at No. 68 Xiangjiang Road, Meihekou City, Jilin Province. It is a pharmaceutical enterprise with chemical injection and cardiovascular and cerebrovascular treatment as its core business. The company was established in 2013 and covers an area of 47890 square meters. It has a small-capacity injection workshop and quality control room with a total construction area of 13232 square meters, it has 2 small-capacity injection production lines (1 ampoule production line and 1 vial production line). For the national high-tech enterprises, the province "specialized new" small and medium-sized enterprises.

The company always regards products as the core driving force to promote the development of the company. In recent years, it has insisted on transformational development and innovative development. At the same time, the company keeps up with the development of the industry, actively develops external technical services, and undertakes multiple corporate ampoules and vials. Entrusted research and development of drugs for injection and subsequent commercial production.

Sunny Novo

Provide full-process drug development technology solutions

Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd. is a listed company on the Science and Technology Innovation Board (688621). It is a comprehensive CRO company that focuses on generic and innovative drug research, is committed to promoting the development of China's pharmaceutical industry with technical services as the core, and provides customers with "pre-clinical and clinical" full-process drug research and development services. From drug discovery, to pharmacological efficacy, pharmaceutical research, to the integration of clinical research resources, the construction of biological sample testing team, and the integration of production and manufacturing capabilities, Sunny has successfully created a full-process CRO service model.

The company's main business covers pharmacological efficacy, clinical research, innovative drug development, generic drug development and consistency evaluation of comprehensive research and development services, including drug discovery, pharmacological efficacy, pharmaceutical research, clinical research and biological analysis. It can carry out complete chemical drug research and development, generic drug consistency evaluation, drug metabolism analysis and evaluation research, peptide drug research and development, clinical bioequivalence test, drug phase I-IV clinical research, biological sample testing, registration declaration (domestic and imported), international cooperation and other services.